Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity - Wikidata - awgldk - TriplyDB

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

http://www.wikidata.org/entity/Q57531180

about

Vaccines for gonorrhea: can we rise to the challenge?Meningococcal Vaccinations Meningococcal B vaccination strategies and their practical application in Italy Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage The Evolution of the Meningitis Vaccine Project Structural and Kinetic Characterizations of the Polysialic Acid O-Acetyltransferase OatWY from Neisseria meningitidis Meningococcal carriage and disease--population biology and evolution Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy Recent Progress in the Prevention of Serogroup B Meningococcal Disease.Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.Resolution of a meningococcal disease outbreak from whole-genome sequence data with rapid Web-based analysis methods.Influence of two vaccination campaigns on genetic diversity of invasive Neisseria meningitidis isolates in northern Spain (1997-2008)The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and disease.Carriage rate and effects of vaccination after outbreaks of serogroup C meningococcal disease, Brazil, 2010.Review of meningococcal group B vaccines.Epidemiological profile of meningococcal disease in the United States Clinical and laboratory evidence for Neisseria meningitidis biofilms.Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba A model-based analysis: what potential could there be for a S. aureus vaccine in a hospital setting on top of other preventative measures?Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity Global practices of meningococcal vaccine use and impact on invasive disease.Functional T-cell deficiency in adolescents who experience serogroup C meningococcal disease despite receiving the meningococcal serogroup C conjugate vaccine.Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Genetic diversity and levels of expression of factor H binding protein among carriage isolates of Neisseria meningitidis.Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.Neisseria meningitidis: biology, microbiology, and epidemiology.Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.Clonal analysis of meningococci during a 26 year period prior to the introduction of meningococcal serogroup C vaccines.Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics.A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

P2860

Q21131153-8599622F-C8C2-4C61-87E1-7D1834CDF44C Q26752993-9D93B32D-818A-4702-ABC7-D69FABA00055 Q26770699-951C4336-23FD-437E-AED9-7222C8279079 Q26770707-23C94A30-5D41-4CEE-AF98-65487DF895BB Q26778281-9D075E42-E769-40B7-B31C-BA7AD42C36A8 Q27655942-767A0397-F3ED-4E9E-91FF-4915088A0523 Q28246008-88C9F0A4-BF1A-44B3-8F5B-B5CD803EDC5D Q28741100-60E5038F-2613-4667-B104-D90A0D97BE48 Q28744396-610C423E-0665-4F67-A1F0-193CC6B77ECE Q28972389-4F309952-D5CA-4FC3-B91C-DBC52D65BAEE Q30235040-CE0E3893-1BB2-455A-903E-A15B5BDE6EAC Q30239049-1815BEF7-BC90-4A16-8203-CEC24456B194 Q30431534-6BA0D580-2A63-4E51-9687-EB2C09F8F595 Q30464193-97F3E75D-E43D-43BD-B1F8-B64CC3609009 Q33521231-F8AB2F25-A6C5-4233-BDEC-9F68FA78F607 Q33535924-805A9C84-77B8-47E7-BF16-A6F026C51447 Q33577121-94806E0A-1968-47D0-B938-C9D65F7C8145 Q33646965-8E712A3E-1D18-467F-9CEF-5067A8F26BE2 Q33648635-DDBF4FF7-C9C3-4E46-B369-D4E30AAF56C1 Q33685515-E0EE53CC-A825-4038-8F22-31B392DF8D1F Q33703560-18F16A97-5A32-4ED3-89A8-C6EA2CBA3590 Q33704817-2E4468DB-8472-4EC0-B15C-80318E8CB8C7 Q33714965-6006CD96-F226-4757-B7E3-6BFDF5506F34 Q33806774-516BFE8F-CF28-451B-8903-08E4B2A5522E Q33825722-1E97CB63-8358-481E-BFBF-2772671D465C Q33850840-798186A6-9B33-4831-BD52-8DD0A57E75CF Q33962704-47FCE3F0-21DC-4E9B-88DC-EDD782ED62AB Q34153704-549A453A-07A0-4982-928A-74096E64619E Q34155231-708252EA-16DF-4E77-9C1F-C20DDD523BCD Q34170021-571632F6-3C93-4546-87A2-B6647A23B863 Q34231871-8088BAC6-4D61-429C-801D-332EA0E1DB7A Q34346578-1CC62A73-7DE0-41DF-A870-97E4A275D0AD Q34627685-256EE5F5-3738-45DF-92C0-8501D46EBB13 Q34632986-84F4ADDE-1D6A-4BBA-AE4F-15BFDB871ECA Q34707962-D382F6FE-AC0D-4B33-B39D-16DF32FC2960 Q34721179-C82CCE03-5306-4C31-A579-9DE938F76C87 Q34738958-EDDA3AD2-3799-4871-9104-09F4F8F28012 Q35006862-F6C77EBA-25AC-4E23-8226-5CDEC5B64A6D Q35048994-F9F7DB41-F8B3-4204-B229-23D046AE90E1 Q35181636-ED5D3B07-4CA9-4570-BE7F-D990876C62A7

P2860

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

http://www.wikidata.org/entity/Q57531180

description

im März 2008 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 March 2008

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в березні 2008

@uk

name

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

@en

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

@nl

type

label

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

@en

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

@nl

prefLabel

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

@en

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

@nl

P1433

Q57531180-0F25510F-EC82-4324-8508-D427EEE3BDBC

P1476

Q57531180-A5136F82-88C6-4ADD-9952-3B7588C5B3C3

P2093

Q57531180-04ECA154-F252-4155-BDA5-4C39C1248C57

Q57531180-072BE294-CED6-41A9-8DB9-4661077CB2AC

Q57531180-1AFD8B90-72F6-4A63-B2FD-7C9F66F8AA3D

Q57531180-1F1181DD-2ED9-4E1B-BED1-C5599ED6E775

Q57531180-67182964-3A69-4FA2-9B74-713D76D439FE

Q57531180-7739664D-7340-4637-BA48-44B907305DF3

Q57531180-85160243-52FF-4F08-B982-2C69896E2222

Q57531180-89AD7516-21E5-4A6B-85D6-737FE320DE38

Q57531180-9DB1D846-F7B3-48F5-9CF6-A16F7F37D848

Q57531180-A8D5AFFE-EC6B-43A7-938B-82EF8C4091F1

P2860

Q57531180-0192EAC5-31E5-4105-AB44-54B9A71340E2

Q57531180-15D15895-1B54-4088-9ED2-592E870D2ABD

Q57531180-26882CCC-21AA-4C69-8D17-5C5331F82BEC

Q57531180-2734E0B2-5BF6-49E2-B542-041B5EAB74F3

Q57531180-2888BB7F-597B-4432-ACB7-E5187B429A76

Q57531180-2F35F252-E07F-4F1F-A43F-61085D241427

Q57531180-4E2D36CA-398F-43C5-A458-F9CFC5FABED9

Q57531180-5676BB02-1332-48AC-B054-0B72A2FA5CBE

Q57531180-6D3EC257-F7A5-4B13-823E-33F4819C8159

Q57531180-7205E59E-BA14-456D-AB1E-4D30E08BD023

P304

Q57531180-F155361D-7CF5-49E3-A986-877A10C64B0A

P31

Q57531180-BD6AD30B-0EDE-4462-B6C4-6812DF6E80C1

P356

Q57531180-FD353991-DF3B-4415-9B8E-ECDEB4A7E8D1

P407

Q57531180-9A7F79D1-DD05-4C2D-8B13-9FCE22F09E3D

P433

Q57531180-16E28A2C-0C9F-4AE0-9F74-12AECB48BE5D

P478

Q57531180-EE3FF35C-EC38-4B25-BA73-C2DFC5AE57E8

P50

Q57531180-6E8BD8D7-DBB5-458C-8FE3-3DD7B6FF9AB0

Q57531180-BD07122D-26C2-4D5F-BE55-4DEA4301DF0A

Q57531180-D49F5C7B-77AE-46CB-A5BA-27816C4AB74E

P577

Q57531180-4F67EDC6-E0E8-4304-AD44-926E8F6E1920

P698

Q57531180-BB64D64B-5C31-4601-A47B-E9B65FAC4144

P921

Q57531180-7D05D7DE-3703-4B58-9076-C6DA3A3D6D75

P932

Q57531180-760BC7A1-2850-416B-8E00-3F787CDE9549

P356

P1433

The Journal of Infectious Diseases

P1476

Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity

@en

P2093

A Mark Walker

http://www.w3.org/2001/XMLSchema#string

Ana Belén Ibarz-Pavón

http://www.w3.org/2001/XMLSchema#string

David Baxter

http://www.w3.org/2001/XMLSchema#string

Derrick W Crook

http://www.w3.org/2001/XMLSchema#string

Dlawer A A Ala'aldeen

http://www.w3.org/2001/XMLSchema#string

Edward Kaczmarski

http://www.w3.org/2001/XMLSchema#string

J Claire Cameron

http://www.w3.org/2001/XMLSchema#string

J Simon Kroll

http://www.w3.org/2001/XMLSchema#string

James M Stuart

http://www.w3.org/2001/XMLSchema#string

Jenny Maclennan

http://www.w3.org/2001/XMLSchema#string

P2860

mlstdbNet - distributed multi-locus sequence typing (MLST) databases

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Improved rate of isolation of Neisseria meningitidis by direct plating of pharyngeal swabs

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

Haemophilus influenzae type b conjugate vaccines.

Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

The UK Hib vaccine experience

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis.

First report of capsule replacement among electrophoretic type 37 Neisseria meningitidis strains in Italy

P304

737-743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/527401

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

197

http://www.w3.org/2001/XMLSchema#string

P50

Stuart C. Clarke

Meirion R Evans

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18271745

http://www.w3.org/2001/XMLSchema#string

P921

P932

6767871

http://www.w3.org/2001/XMLSchema#string